Nalirifox vs folfirinox

FOLFIRINOX versus g. First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic

The safety profiles were comparable, although less neutropenia was reported with NALIRIFOX than FOLFIRINOX (24% with NALIRIFOX vs 46% with FOLFIRINOX). However, in clinical practice most patients receive modified FOLFIRINOX (mFOLFIRINOX) that includes a dose reduction aiming to improve tolerability without compromising efficacy, which could be

The only difference between [NALIRIFOX and FOLFIRINOX] is that we re replacing the free form of irinotecan [in FOLFIRINOX] with liposomal irinotecan [in NALIRIFOX], which tends to be retained

Systematic review: NALIRIFOX and FOLFIRINOX may provide similar efficacy as first-line treatment for patients with metastatic pancreatic

NALIRIFOX is similar to FOLFIRINOX; it has similar efficacy and survival benefit compared with FOLFIRINOX but different toxicity profiles. What

FOLFIRINOX), NALIRIFOX does not seem to raise the bar, but rather exposes patients and health-care systems to financial toxicities.

by C Morizane 2024Recently, in a randomised, open-label, Phase 3 trial, first-line NALIRIFOX Comparison of FOLFIRINOX vs gemcitabine plus nab-paclitaxel as

NALIRIFOX (5-fluorouracil, folinic acid [leucovorin], liposomal irinotecan, and oxaliplatin) is highly similar to FOLFIRINOX, but it employs liposomal

by A Hernández-Blanquisett 2024 Cited by 4PRODIGE 4/ACCORD 11: FOLFIRINOX vs. Gemcitabine Alone. FOLFIRINOX NALIRIFOX, and 387 were included in the control arm [19].